Berger Financial Group Inc Reduces Position in Johnson & Johnson $JNJ

Posted by George Bondi on Jul 8th, 2026

Berger Financial Group Inc lowered its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 18.6% in the first quarter, Holdings Channel.com reports. The institutional investor owned 40,263 shares of the company’s stock after selling 9,209 shares during the period. Berger Financial Group Inc’s holdings in Johnson & Johnson were worth $9,842,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. Steigerwald Gordon & Koch Inc. grew its position in shares of Johnson & Johnson by 0.5% during the first quarter. Steigerwald Gordon & Koch Inc. now owns 114,842 shares of the company’s stock worth $28,072,000 after acquiring an additional 564 shares during the last quarter. GM Advisory Group LLC boosted its stake in Johnson & Johnson by 6.6% during the 1st quarter. GM Advisory Group LLC now owns 14,495 shares of the company’s stock worth $3,543,000 after purchasing an additional 892 shares during the period. AdvisorShares Investments LLC grew its position in Johnson & Johnson by 23.6% during the 1st quarter. AdvisorShares Investments LLC now owns 3,778 shares of the company’s stock worth $923,000 after purchasing an additional 722 shares during the last quarter. Mount Vernon Associates Inc. MD increased its stake in Johnson & Johnson by 6.6% in the first quarter. Mount Vernon Associates Inc. MD now owns 2,186 shares of the company’s stock valued at $534,000 after purchasing an additional 135 shares during the period. Finally, NBT Bank N A NY raised its holdings in shares of Johnson & Johnson by 0.6% in the first quarter. NBT Bank N A NY now owns 108,041 shares of the company’s stock valued at $26,410,000 after buying an additional 640 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president owned 114,288 shares in the company, valued at $27,560,551.20. This trade represents a 8.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $267.35 on Wednesday. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. The stock’s 50 day moving average is $235.09 and its two-hundred day moving average is $232.13. Johnson & Johnson has a twelve month low of $154.21 and a twelve month high of $269.43. The firm has a market capitalization of $643.56 billion, a PE ratio of 30.91, a P/E/G ratio of 2.54 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. The business had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The company’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same period in the prior year, the business posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Research analysts anticipate that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend was Tuesday, May 26th. Johnson & Johnson’s dividend payout ratio is 61.97%.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on JNJ shares. Guggenheim raised their price target on Johnson & Johnson from $266.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, June 26th. Argus increased their price objective on Johnson & Johnson from $240.00 to $275.00 and gave the stock a “buy” rating in a research report on Thursday, April 16th. Wells Fargo & Company lifted their target price on Johnson & Johnson from $240.00 to $263.00 and gave the company an “overweight” rating in a research note on Wednesday, April 15th. Leerink Partners upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price target for the company in a research note on Wednesday, May 13th. Finally, Barclays increased their price target on Johnson & Johnson from $234.00 to $255.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 15th. Twenty analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $257.13.

View Our Latest Stock Report on Johnson & Johnson

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: Investors are buying JNJ ahead of earnings, helped by a higher company outlook, a recent analyst price-target increase, and expectations for another solid quarter. Johnson & Johnson (JNJ) Could Be 34% Below Fair Value Following IMAAVY Update
Positive Sentiment: Wall Street commentary says JNJ’s recent record run reflects rising price targets and strong institutional buying, reinforcing the bullish view on the stock. Johnson & Johnson (JNJ) Stock Surges Past Record High as Wall Street Raises Price Targets
Positive Sentiment: Analysts expect J&J to report higher second-quarter earnings, which is helping sentiment into the July 15 earnings release. Johnson & Johnson Likely To Report Higher Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Neutral Sentiment: Recent articles continue to frame Johnson & Johnson as a defensive healthcare name with dependable dividend income, which may support holding interest but is not a direct catalyst. Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
Negative Sentiment: One market note highlighted unusual put option activity after JNJ’s runup, suggesting some traders are positioning for a pullback or near-term volatility. Unusual Put Option Activity in Johnson & Johnson After JNJ Stock’s Recent Runup

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.